JP2020506239A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506239A5
JP2020506239A5 JP2019563340A JP2019563340A JP2020506239A5 JP 2020506239 A5 JP2020506239 A5 JP 2020506239A5 JP 2019563340 A JP2019563340 A JP 2019563340A JP 2019563340 A JP2019563340 A JP 2019563340A JP 2020506239 A5 JP2020506239 A5 JP 2020506239A5
Authority
JP
Japan
Prior art keywords
composition
mci
formulation
chelate
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506239A (ja
JP7792746B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017082 external-priority patent/WO2018148209A1/en
Publication of JP2020506239A publication Critical patent/JP2020506239A/ja
Publication of JP2020506239A5 publication Critical patent/JP2020506239A5/ja
Priority to JP2022164581A priority Critical patent/JP2022183238A/ja
Priority to JP2024209612A priority patent/JP2025036436A/ja
Application granted granted Critical
Publication of JP7792746B2 publication Critical patent/JP7792746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563340A 2017-02-08 2018-02-06 治療用骨剤の使用方法 Active JP7792746B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022164581A JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762456191P 2017-02-08 2017-02-08
US62/456,191 2017-02-08
PCT/US2018/017082 WO2018148209A1 (en) 2017-02-08 2018-02-06 Method of use for therapeutic bone agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022164581A Division JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A Division JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Publications (3)

Publication Number Publication Date
JP2020506239A JP2020506239A (ja) 2020-02-27
JP2020506239A5 true JP2020506239A5 (enExample) 2021-01-21
JP7792746B2 JP7792746B2 (ja) 2025-12-26

Family

ID=63107036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563340A Active JP7792746B2 (ja) 2017-02-08 2018-02-06 治療用骨剤の使用方法
JP2022164581A Pending JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A Pending JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022164581A Pending JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A Pending JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Country Status (5)

Country Link
US (1) US11813339B2 (enExample)
EP (1) EP3579886A4 (enExample)
JP (3) JP7792746B2 (enExample)
CA (1) CA3052973C (enExample)
WO (1) WO2018148209A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
EP1475105A1 (en) 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
WO2011149844A1 (en) * 2010-05-24 2011-12-01 Iso Therapeutics Group Llc Delivery of high dose therapeutic radioisotopes to bone
CN105792836A (zh) * 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
ES2949277T3 (es) * 2013-10-07 2023-09-27 Igl Pharma Inc Proceso de preparación de agentes óseos terapéuticos de alta pureza
JP6930922B2 (ja) 2015-05-25 2021-09-01 アイジーエル ファーマ，インコーポレイティド 放射性同位体用ｄｏｔｍｐキット製剤

Similar Documents

Publication Publication Date Title
Harrison Anaesthetic-induced malignant hyperpyrexia: a suggested method of treatment
Ward Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels
JP2020033360A5 (enExample)
Suit et al. Radiation therapy of soft tissue sarcomas
JP2019528320A5 (enExample)
JP2018076328A5 (enExample)
JP2020505408A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2014515373A5 (enExample)
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2016509050A5 (enExample)
Traino et al. Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism
JP7068222B2 (ja) 高純度治療用骨剤
JP2019123731A5 (enExample)
Kamaleshwaran et al. Radiosynovectomy of proximal interphalangeal joint synovitis in rheumatoid arthritis treated with rhenium-188 labeled tin-colloid and imaging with single-photon emission computerized tomography/computed tomography: a first case report
JP2020506239A5 (enExample)
JP2019535830A5 (enExample)
DE3344086A1 (de) Verwendung von azaspirogermanium-verbindungen zur behandlung von arthritis
Volf Experimental background for prompt treatment with DTPA of 239Pu-contaminated wounds
TW202220650A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物
US20240165280A1 (en) Methods for treatment of cancers
Hamilton Production of immunity in the cat against lungworm disease by administration of third-stage larvae
RU2017132445A (ru) Дозы панобиностата для множественной миеломы
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
Uzlu et al. QT and QTc prolongation and decreased heart rate after IV administration of levamisole hydrochloride in conscious rabbits